Compare Pfizer Inc (PFE) vs First Trust Cloud Computing ETF (SKYY) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

SKYY trades at $136.02, down 0.06% on the day, with a bullish technical signal driven by moving averages. The ETF offers diversified exposure to the cloud computing sector, though key valuation and profitability metrics are not disclosed in the provided data. Recent news highlights ongoing investor interest in technology ETFs and the growth potential of AI-driven cloud platforms.

The outlook for SKYY is supported by strong inflows into technology ETFs and enterprise AI spending, but risks include sector volatility and competitive pressures. Analyst coverage remains positive on cloud computing's long-term growth, though specific price targets and institutional holdings data are needed for a fuller assessment.